CFR Chemaphor Inc.

OTTAWA, Oct 1 /CNW/ -- Listing: TSX Venture ExchangeSymbol:   CFR OTTAWA, Oct 1 /CNW/ - Chemaphor Inc. (TSX Venture: CFR) today announced that it will rename its wholly owned subsidiary, 7552882 Canada Inc., "Avivagen Animal Health Inc." to focus on the commercialization of Chemaphor's companion animal health products, including the recently in-licensed Vet-Stem stem cell treatment and Chemaphor's own Oximunol™ Chewables for dogs. Chemaphor is now in the final stages of planning the launch of the first product entries into the companion animal marketplace, currently expected to occur later this fall. This announcement officially marks the transition of Chemaphor's focus from that of a late-stage R&D operation into a commercial enterprise. In keeping with the progress of Chemaphor from an R&D-focused company into one emphasizing sales and revenue generation, Chemaphor is also announcing certain senior management changes. Mr. David Hankinson, currently Co-Chairman of the Chemaphor board of directors, is vacating that role to become the CEO of both Avivagen and Chemaphor. David Hankinson brings extensive marketing and sales experience gained in the pharmaceutical sector and has successfully managed several start-up companies. Notably, he successfully built Solvay Pharma (Canada) into a profitable company with major sales. Mr. Hankinson replaces current Chemaphor CEO, Dr. Paul Dick, who will also step down as a member of the Chemaphor board of directors. Dr. Dick joined Chemaphor two years ago with a mandate to guide the company from a late stage research and development focus to commercialization. With the successful completion of that goal, Dr. Dick is expected to remain associated with Chemaphor as an advisor while he engages in other, independent consulting opportunities and assignments. Mr. Amin Khalifa, currently Co-Chairman of the board, takes over as Chairman. Mr. Khalifa has been on the board of directors of PetSmart Inc. for approximately six years. He also brings significant commercial and financial experience from his past tenure as CFO for three US listed companies; Beckman Coulter, Apria Healthcare and Leap Wireless. Mr. Khalifa commented; "I want to wish Paul Dick all the best in his future endeavors. He has been instrumental in helping Chemaphor develop its products and in building strong relationships with both our commercial and research partners. Chemaphor's focus now will be on taking to market products of Chemaphor research and acquired products, targeting both animal and human wellness." The board of directors of Chemaphor wishes to thank Dr. Dick for his vision and guidance during the transition of Chemaphor into a commercial enterprise. About Chemaphor Chemaphor, a wellness company, is committed to developing and delivering products to humans and animals to assist in optimizing health and daily quality of life. From this platform Chemaphor is advancing product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com Forward Looking StatementsThis news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Chemaphor's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Chemaphor or its management. The forward-looking statements are not historical facts, but reflect Chemaphor's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. table valign="top" border="0"trtd valign="top" align="left"bChemaphor Inc.br//bGraham Burtonbr/613-990-0969br/a href="mailto:g.burton@chemaphor.com"g.burton@chemaphor.combr/br//a/td td align="right" /td td align="right" /td td valign="top" align="left"bInvestor Relations  br//bSylvain Archambault br/President br/Evolution Group Inc.br/Tel.: 1-866-703-4887 br/a href="mailto:s.archambault@evolutiongrp.com"s.archambault@evolutiongrp.combr//a/td/tr/table

Copyright